Bora Pharmaceuticals continues its robust expansion by acquiring a significant operational stake in Tanvex BioPharma, a deal set to close in early 2025. This strategic acquisition positions Bora as the largest shareholder in Tanvex, granting the company access to a commercial-scale production
The acquisition of a 30.5% stake in Tanvex Biopharma by Bora Pharmaceuticals is a pivotal development in the biotech sector. As the largest single corporate shareholder in Tanvex, Bora aims to leverage this strategic partnership to enhance its competitive edge in the global biopharmaceutical
The recent decision by the Supreme Court to overturn the Chevron doctrine marks a significant shift in administrative law, with profound implications for the healthcare industry, particularly for federal regulators like the FDA (Food and Drug Administration) and the CMS (Centers for Medicare &
The early-stage biotech investment landscape has undergone substantial changes in recent years. From the buoyant investment period during the pandemic to the current stabilization at pre-pandemic levels, the sector faces a mix of challenges and evolving strategies. One of the most significant
The Korea Biopharma Excellence Awards (KBEA) 2024 marked a significant moment for Avantor, a leader in providing mission-critical products and services across life sciences and advanced technologies. Avantor’s recognition at these awards underscores their unwavering commitment to innovation and
In recent years, the biotech sector has faced significant challenges in the initial public offering (IPO) market. The economic downturn and financial uncertainties have created a tough environment for companies looking to go public. However, some biotech firms, such as Bicara Therapeutics and Zenas
